Axol Biosciences, an Edinburgh, Scotland, UK‑based provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and disease research, raised $2.8 million in funding.

The round was led by BroadOak Capital Partners, with participation from Roslin Foundation.

The company intends to use the funds to accelerate its next phase of growth, supporting the expansion of its US operations and commercial presence.

Led by CEO Liam Taylor and CFO Oliver Richardson, Axol Bioscience develops and supplies functional iPSC‑derived cells, reagents, and specialist services to pharmaceutical, biotech, CROs, and academic institutions worldwide. It has recently established itself as a player in provision of physiologically relevant iPSC‑derived models for neurodegenerative disorders including Huntington’s disease and sporadic amyotrophic lateral sclerosis (ALS/MND), addressing unmet needs in neurodegenerative disease research.